TEAEs did not increase with repeated cycles.<h4>Conclusions</h4>Repeated cycles of rozanolixizumab resulted in consistent, clinically meaningful improvements across cycles in MG-specific outcomes with an acceptable safety profile, supporting rozanolixizumab as a treatment option for adults with AChR and MuSK autoantibody-positive gMG. Here, MUSK is linked to myasthenia gravis.